Distilbène : une étude sur trois générations

Le DES, en savoir plus…

DES, trois initiales qui ont bouleversé la vie de trois générations depuis les années 1950. Après vingt ans de combats judicaires, les victimes du distilbène ont à nouveau la parole. Pour la première fois en France, une étude épidémiologique sur les trois générations concernées est menée sur les effets de cette hormone de synthèse.

L’enquête nationale sur les conséquences du DES, commençée en avril 2013, cible notamment à évaluer le lien entre l’exposition au distilbène in-utero et le risque de développement du cancer du sein, et couvre les trois générations victimes de ce médicament.

Le Distilbène DES, en savoir plus

BPA Exposure In-Utero increases Prostate Cancer Risk as Adult

The increased risk can be traced to prostate stem and progenitor cells

Early BPA exposure increases risk of adult cancer
Dr. Gail Prins, researcher at UIC College of Medicine

In-Utero exposure to bisphenol A (BPA) causes an increased cancer risk in an animal model of human prostate cancer, according to researcher Dr. Gail Prins, professor of physiology and director of the andrology laboratory in urology at University of Illinois at Chicago College of Medicine.

Previous studies by Dr. Prins and colleagues using rats showed that exposure to elevated estrogen or BPA during embryonic development increased the rate of prostate cancer later in life.  To determine if there was a link in humans, Dr. Prins developed a new animal model using human prostate stem cells implanted into mouse “hosts.”  ”

Read Early BPA exposure increases risk of adult cancer
by Sharon Parmet, UIC, June 17, 2013

BPA is an estrogen-like endocrine-disrupting chemical very similar to DES. Read one of our previous blog post: “Endocrine Disruptors permanent effect on Obesity through at least three Generations“.

Taking anti-depressants in early Pregnancy linked to Child Heart Defects

Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study

Anti-depressants pregnancy 'risk'
Do you think those extra risks are really worth taking?

Children born to women taking anti-depressants in early pregnancy have a small but important increased risk of heart defects, Danish researchers say.


To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations.

Population based cohort study.

493 113 children born in Denmark, 1996-2003.

Main outcome measure
Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005.

Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low—for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI.

There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI.

Related posts:

Sadly for many DES daughters having their own children is not possible! Many of us who have experienced miscarriages, want to have kids but are struggling or unable to…

The Moment when you look back and understand why Things happened the Way they did…

Art Jonak: Innovator ☈ Imitated, never duplicated✩

Art Jonak, Founder MLM Mastermind Event☍ Speaker☄ Thought Leader☼ Globe Trotter✈ (79 countries) Optimist☮ http://Facebook.com/ArtJonak ♥ Entrepreneur☂ Imitated, never duplicated
” Keep going forward, you’ll get there… and there will come a moment when you look back and understand why things happened the way they did ” by @ArtJonak

Art Jonak Daily MotivationFacebookTwitterWebsite – our Quotes

After DES DiEthylStilbestrol : tracking the Harms of a Prenatal Drug Exposure

NCI Cancer Bulletin Archives 2011

After DES: Tracking the Harms of a Prenatal Drug Exposure
NCI Cancer Bulletin for October 18, 2011

Kari Christianson was 23 years old when she first heard of a drug called diethylstilbestrol, or DES.

It was the spring of 1972, and Dr. Arthur Herbst – who had recently published the study Adenocarcinoma of the Vagina — Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Women  suggesting that the drug, when used by pregnant women, might cause cancer in their offspring years later – was on television discussing concerns about the drug. For decades, doctors had prescribed DES to millions of healthy pregnant women, including Kari’s mother, based on unsubstantiated claims that it reduced the complications of pregnancy. “

Continue reading Kari’s story and Edward Winstead‘s post:
After DES: Tracking the Harms of a Prenatal Drug Exposure
NCI Cancer Bulletin for October 18, 2011.

More DES DiEthylStilbestrol Resources

BPS alters Hormones at Low Doses

Bisphenol S Disrupts Estradiol-Induced Nongenomic Signaling in a Rat Pituitary Cell Line: Effects on Cell Functions

BPA replacement alters hormones at low doses, study finds
Ultrasound images are printed on thermal paper that contains BPS

Just like the controversial Bisphenol A that it designed to replace, Bisphenol S chemical used in cash register receipts and other consumer products messes with hormones, according to research by University of Texas scientists. The study is the first to link low concentrations of BPS – a BPA alternative – to disruption of estrogen, spurring concern that it might harm human health. Researchers exposed rat cells to levels of BPS that are within the range people are exposed to…. and, just like BPA, the compound interfered with how cells respond to natural estrogen, which is vital for reproduction and other functions.

Read BPA replacement alters hormones at low doses, study finds
by Brian Bienkowski, Environmental Health News, Jan. 17, 2013.

Cervical Cancer: Screening Pap Smears tied to higher Cure Rate

Population based cohort study, Sweden, 2012

Screening Pap Smears tied to higher Cure Rate
Screening Pap Smears tied to higher Cure Rate

Another good reason for women to have regular Pap smears.: ” Women with screen-detected cervical cancer had a 26% absolute increase in cure rate as compared with women who were symptomatic at diagnosis, results of a Swedish study showed. ”


To determine whether detection of invasive cervical cancer by screening results in better prognosis or merely increases the lead time until death.

Nationwide population based cohort study.


All 1230 women with cervical cancer diagnosed during 1999-2001 in Sweden prospectively followed up for an average of 8.5 years.

Main outcome measures
Cure proportions and five year relative survival ratios, stratified by screening history, mode of detection, age, histopathological type, and FIGO (International Federation of Gynecology and Obstetrics) stage.

In the screening ages, the cure proportion for women with screen detected invasive cancer was 92% (95% confidence interval 75% to 98%) and for symptomatic women was 66% (62% to 70%), a statistically significant difference in cure of 26% (16% to 36%). Among symptomatic women, the cure proportion was significantly higher for those who had been screened according to recommendations (interval cancers) than among those overdue for screening: difference in cure 14% (95% confidence interval 6% to 23%). Cure proportions were similar for all histopathological types except small cell carcinomas and were closely related to FIGO stage. A significantly higher cure proportion for screen detected cancers remained after adjustment for stage at diagnosis (difference 15%, 7% to 22%).

Screening is associated with improved cure of cervical cancer. Confounding cannot be ruled out, but the effect was not attributable to lead time bias and was larger than what is reflected by down-staging. Evaluations of screening programmes should consider the assessment of cure proportions.

Read Screening Pap Smears Tied to Higher Cure Rate, by Charles Bankhead, MedPage Today, March 02, 2012

Sources: Screening and cervical cancer cure: population based cohort study, BMJ, March 01, 2012

Prenatal Exposures: should you be worried?

via “Prenatal Exposures Never Die”: the blog about epigenetics, autism, and the multigenerational tragedy of prenatal pharmaceutical use

Prenatal Exposures: Should You Be Worried?
Autism Exposed: “The” blog about epigenetics, autism, and the multigenerational tragedy of prenatal pharmaceutical use – PrenatalExposures.Blogspot.co.uk

Jill Escher from Autism Exposed addresses those questions in PrenatalExposures.Blogspot.co.uk latest bog post…
read Prenatal Exposures: Should You Be Worried?

Find out more about DES exposure and the long-term health effects associated with prenatal exposure to DES drug.

DES DiEthylStilbestrol Resources

Marketing of Madness

Official preview video, 8 Dec 2009

If you, a loved one, or anyone you know is taking drugs recommend by a MD or Psychiatrist for Anxiety, Depression, Bi-Polar, ADHD, Obsessive Compulsive, Schizophrenia etc… then this film is an absolute must watch.

  • Video by foodmatterstv, Published on 8 Dec 2009
  • This is the definitive documentary on the psychiatric drugging industry. Here is the real story of the high income partnership between psychiatry and drug companies that has created an $80 billion psychotropic drug profit centre. But appearances are deceiving. How valid are psychiatrists diagnoses and how safe are their drugs? Digging deep beneath the corporate veneer, this three-part documentary exposes the truth behind the slick marketing schemes and scientific deceit that conceal dangerous and often deadly sales campaign. “
  • DVDNews – WebsiteFacebook
  • Watch our DES Videos in English playlist on YouTube.

Raise your Hand if you have any Financial Conflicts of Interest in this Decision…

Dan Berger is Cartoonist behind Natural News

This cartoon seeks to portray the scientific fraud that goes on day to day at the FDA as so-called drug safety review panels are convened to declare dangerous drugs as being perfectly safe – @HealthRanger.

Dan Berger is Cartoonist behind Natural News.

Over the last decade or so, the FDA has quietly become an agent of organized scientific fraud designed to promote the profits of drug companies at the expense of public health. One of the ways this is accomplished is by rigging drug review panels with industry “experts” who maintain financial ties to pharmaceutical companies.

Continue reading: Conflicts of Interest
by Mike Adams, the Health Ranger.

All our posts about big pharma, drugs, DrugMoney, the FDA.
See more comics

On Flickr®

Watch the Diaporama, and the health comics album on DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact
Email your photos to des.daughter@gmail.com with a short description and title :-)